Holiday Sale | Save 50%
Holiday Sale | Save 50%
Published

Mesoblast's RYONCIL Makes History: First MSC Therapy FDA-Approved with 70% Response Rate in Critical Child Disease

Summary by stocktitan.net
Breakthrough therapy RYONCIL receives historic FDA approval for treating steroid-resistant GvHD in children, showing remarkable 70% response rate in clinical trials.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics